INTRODUCTION
============

The development of cancer is a step-wise accumulation of genetic and epigenetic alterations including chromosome rearrangements that, in most cases, involve proto-oncogenes. Production of multiple copies of particular gene or gene amplification (*amp*) is one of the basic mechanisms that lead to over expression of oncogenes \[[@b1-bjmg-14-02-17]\]. It is a frequent event in solid tumors but is rather rare in malignant hemopathies \[[@b1-bjmg-14-02-17],[@b2-bjmg-14-02-17]\]. Genes with affinity to genomic over representation in myeloid malignancy such as acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) and others, are *c-MYC*, *MLL* and more rarely *RUNX1* and *ETV6*\[[@b3-bjmg-14-02-17]--[@b7-bjmg-14-02-17]\].

The *MLL* gene (located in region 11q23) is a transcriptional factor that normally regulates expression of mir-196b, a hematopoietic microRNA located within the HoxA cluster \[[@b8-bjmg-14-02-17]\]. The *MLL* over expression resulting from *amp* of *MLL (amp MLL*) leads to over expression of the functionally related HOX genes, provoking an increased cell proliferative capacity and survival, as well as a partial block in differentiation \[[@b4-bjmg-14-02-17],[@b8-bjmg-14-02-17]\]. The presence of additional *MLL* copies in the genotype of the patients with MDS increases the transformation potential of the affected cell clones, which results in evolution to AML \[[@b4-bjmg-14-02-17]\].

The MYC proteins play a well defined role as the components of signal transduction pathways promoting both cell proliferation and apoptosis \[[@b9-bjmg-14-02-17],[@b10-bjmg-14-02-17]\]. The *c-MYC* gene (located in region 8q24) is frequently over expressed in human cancers, but the downstream events contributing to the tumor genesis remain incompletely understudied \[[@b3-bjmg-14-02-17],[@b10-bjmg-14-02-17]\]. The next step of the disease progression would be if the *amp* of *c-MYC* (*amp c-MYC*) and *amp MLL* is accompanied by proven over expressions of corresponding genes \[[@b4-bjmg-14-02-17],[@b10-bjmg-14-02-17]\].

Total or partial trisomy is an unbalanced karyotypic anomaly which is more frequently a secondary event in the development of a neoplasia \[[@b11-bjmg-14-02-17]\]. Trisomy 8 (+8) occurs in 10 to 20% of the cases with myeloid malignances in contrast to the more rare but non random aberration, trisomy 11 (+11) \[[@b12-bjmg-14-02-17]--[@b14-bjmg-14-02-17]\]. According to the United Kingdom Medical Research Council (MRC) criteria and World Health Organization classification-based prognostic scoring system, the prognostic value of these anomalies for achieving a complete remission in AML and for transformation in MDS is intermediate, but if +8 or +11 is attendant with over representation or/and amplification of *c-MYC* and *MLL* genes, the prognosis assessment would be worse \[[@b4-bjmg-14-02-17],[@b10-bjmg-14-02-17],[@b15-bjmg-14-02-17]--[@b16-bjmg-14-02-17]\]. The final step in the malignant cell clone development that predicts resistance to therapy is karyotype complexity \[[@b15-bjmg-14-02-17]\]. The 8q24 (*c-MYC*) and 11q23 (*MLL*) gains were observed in about 40% of the cases with AML and complex karyotype \[[@b17-bjmg-14-02-17]\]. The objective of this study was to investigate the correlation between cytogenetically defined +8 or +11 in karyotypes at a different level of clonal cell development with molecular genetically proved *amp c-MYC* or *amp MLL* genes.

PATIENTS AND METHODS
====================

Patient Group
-------------

A total of 26 patients aged 16 to 82 years (median about 62 years) were included in this study. The distribution at diagnosis was: 16 patients with overt AML, seven with secondary AML after MDS (sAML) and three with different types of MDS. Eighteen patients had +8; in half of them the tri- or tetrasomy 8 was a sole cytogenetic abnormality. There were additional karyotipical aberrations in the other nine cases. It was the only anomaly in three of the six cases with +11; the karyotypes in the other three cases were more complicated. Also included were two additional cases with complex karyotypes suspected for *amp MLL*. All patients with AML below or equal to 65 (≤65) years of age were treated with induction therapy consisting of antharacycline (Idarubicine, Farmorubicine or Mitoxantrone) and cytarabine according to the standard protocols. Patients above 65 (\>65) years of age received chemotherapy with Cytosar only. Patients with MDS before transformation to AML received supportive therapy and after transformation were treated with standard chemotherapy. The study was approved by the local Ethics Committee of the National Hospital for Hematological Diseases. All participants had given written informed consent.

Cytogenetic Analysis
--------------------

Routine cytogenetic analysis was performed on metaphase chromosomes from bone marrow samples using a direct method and after short-term 24- or 48 hour-culturing \[[@b18-bjmg-14-02-17]\]. A minimum of 15 bone marrow metaphase cells were analyzed in each patient using GTG differentially-stained chromosomes at a discriminatory level of 300--400 bands per haploid count. Karyotypic findings were interpreted and described according to the International System for Human Cytogenetic Nomenclature (ISCN, 2009) \[[@b19-bjmg-14-02-17]\].

Fluorescent *In Situ* Hybridization (FISH)
------------------------------------------

Fluorescent *in situ* hybridization was performed according to the standard manufacturer's protocol (Vysis®; Abbot Molecular Inc., Abbott Park, IL, USA) on inter-phase nuclei in suspension after a routine cytogenetic procedure and stored at −20°C. Locus-specific dual color *MLL* break apart rearrangement probe and *c-MYC* break apart rearrangement probe (Vysis®; Abbot Molecular Inc.) were used, and no less than 200 inter-phase nuclei per probe were analyzed. In these probes, the 5' portion of the *MLL* gene (or *c-MYC*) was labeled in green, and the 3' portion in red. Thus, the presence of two normal gene signals in the cell was visualized as dual composite signals (red + green). The gene deletion was detected as a single composite signal, and +8 (or +11) as three composite signals. The presence of more than three composite signals was considered as a *MLL* (or *c-MYC*) gene *amp*. We recognized amplification level as a significant if *amp* were observed in more than 10% of interphase nuclei, under the 10%, as a low level *amp*.

RESULTS
=======

Solely Tri- or Tetrasomy 8
--------------------------

In nine of 18 patients with an additional chromosome 8, this aberration was an isolated clonal anomaly in the karyotype: seven patients with +8 and two patients with tetrasomy 8. The FISH analysis does not show significant *amp c-MYC* in cases 1 through 7 ([Table 1](#t1-bjmg-14-02-17){ref-type="table"}). In the karyotype of patients 1 to 4, the +8 aberration occurred in a minor cell clone (from 10 to 33% of the analyzed metaphases). Correlation between the number of *c-MYC* fluorescent signals in the interphase nuclei and the cytogenetically detected +8 metaphases in the first four patients showed absence or no significant proliferative advantage of the aberrant cell clone. In cases 5 to 7, the cell clone with the +8 anomaly had a proliferative advantage. Only two of our patients with solely +8 and without *amp c-MYC* have achieved a hematological remission. The other two patients from this group did not receive optimal dose chemotherapy due to complications during the neutropenic phase.

In patients 8 to 10, a karyotype progression from tri- to tetrasomy 8 or from partial clonality to total expansion of the aberrant cell clone was observed. Tetrasomy 8 in these cases was accompanied by *amp c-MYC.* In two patients with MDS and expansion of the cell clone harboring +8 and *amp c-MYC*, the disease evolved to AML.

Trisomy 8 in the Karyotype With Additional Aberrations
------------------------------------------------------

Seven of eight patients (11 through 17) with +8 and additional chromosome aberrations, had a different level of *amp c-MYC*: two with low (under 10%) and five with more than 10%. Coincidence of composite chromosome anomalies and *amp c-MYC* in most of the cases correlate with transformation of MDS to AML and short survival (about 3 months) without achieving a hematological remission. Only one of the patients (17) with MDS-RARS (refractory anemia with ring sideroblasts) and low level of *amp c-MYC*, had comparatively long (13 months) overall survival (OS) despite of his advanced age.

In conclusion, a different level of a*mp c-MYC* was observed in 12 of 18 (66.7%) patients with +8. The karyotypes of patients with a significant level of a*mp c-MYC* demonstrated progressive chromosome complications.

Trisomy 11 and Suspicion of *Amp MLL* Complex Karyotype
-------------------------------------------------------

In two of the six cases with total or partial +11 expansion of the affected cell clone was observed. In four cases, a significant *amp MLL* was recorded. Two patients with +11 (5 and 6) did not have a significant *amp MLL* ([Table 2](#t2-bjmg-14-02-17){ref-type="table"}). The median OS in the patient group with the low level of *amp MLL* was longer than that of the other patients with +11 (6 *vs.* 2 months. respectively).

In the two cases with suspected *amp MLL* and complex karyotype and rearrangements on chromosome 11, there were low, 6% and significant, 67%, levels of the *amp MLL.* Both had very short OS due to early death in induction. All patients with *amp MLL* and/or +11 did not achieve remission and had short survival times.

In conclusion, all our patients with +11 demonstrated a different level of *amp MLL*. The significant level of *amp MLL* in this group is correlated with a very short OS.

DISCUSSION
==========

The biological mechanism of the oncoproliferative activity of the +8 cell clones is explained mostly with the gene dosage effect \[[@b20-bjmg-14-02-17]\]. Some authors using microarray techniques observed overexpression of genes located on chromosome 8 in trisomic cells \[[@b20-bjmg-14-02-17],[@b21-bjmg-14-02-17]\]. Further microarray analysis demonstrated that +8 MDS was notable for over expression of immune and inflammatory genes; some of these gene products also have roles in cellular proliferation and differentiation in an angiogenesis, whereas apoptotic inhibitors were down-regulated \[[@b22-bjmg-14-02-17]\]. Another proposed explanation of the biological significance of the extra chromosome 8 was based on the observation of increased copies of the *c-MYC* gene that plays a central role as a downstream mediator of the myeloid leukemogenesis \[[@b23-bjmg-14-02-17]\]. Furthermore, a comparative genomic hybridization ratio measurement revealed that a gain of 8q24 is associated with mutation of the *p53* tumor suppressor gene. The association between the gain at an 8q24 and the *p53* mutation might be attributable to transactivation of the *c-MYC* gene by the *p53* promoter \[[@b24-bjmg-14-02-17]\].

Amplification mechanisms are not yet clearly understood \[[@b1-bjmg-14-02-17]--[@b2-bjmg-14-02-17]\]. Chromosomes have hot fragile sites that break under specific conditions and may be associated with chromosomal instability in cancer as breakpoint sites for translocation, deletion, and amplification \[[@b9-bjmg-14-02-17]\]. Low-level *amp c-MYC* was reported in a number of patients with +8 AML, +8 MDS and chronic myeloid leukemia (CML) in blast phase \[[@b25-bjmg-14-02-17]--[@b27-bjmg-14-02-17]\]. Some authors suggest that *c-MYC* is not the true target of the *amp* but that abundant expression of another gene(s) included in an 8q24 amplicon is the pathogenetically important consequence \[[@b28-bjmg-14-02-17]\].

In most of our overt AML and sAML +8 cases, the visible developmental effects such as aberrant cell clone expansion and the occurrence of additional chromosome deviations are connected with *amp c-MYC* that was observed in 12 of 18 (66.7%) patients. Absence of an *amp c-MYC* was found predominantly in the cases with minor +8 cell clones. We suggest that *amp c-MYC* is a logical result of the development in the proliferating +8 cell populations.

The + 11 is the third most common trisomy in *de novo* AML, which is more frequently associated with two different molecular genetic alterations: partial tandem duplication (PTD) and *amp MLL* gene \[[@b4-bjmg-14-02-17],[@b29-bjmg-14-02-17]--[@b31-bjmg-14-02-17]\]. In most of the cases, the *amp* 11q23 (with or without any microscopically visible alterations) is accompanied by *MLL* gene over expression, which leads to a rapid proliferation of the affected clone and to disease progression \[[@b4-bjmg-14-02-17],[@b31-bjmg-14-02-17]\].

Our group of patients with +11 is quite small to make definitive conclusions. Most of our patients with +11 cell clone expansion also demonstrated an *amp MLL.* This could be explained by the rapid advance of the developmentally processes in the proliferating +11 cell clones. The significant level of *amp MLL* (\>10%) in cases which are suspected of gaining 11q23 in complex karyotype supported our developmental hypotheses.

The prognostic value of +8 and +11 is contradictary. A number of authors defined them as an intermediate, others as an adverse prognostic factor \[[@b11-bjmg-14-02-17]--[@b13-bjmg-14-02-17],[@b15-bjmg-14-02-17]\]. On the other hand, in most of the publications, the presence of *amp c-MYC* and *amp MLL* correlate with disease progression and poor risk for patients with myeloid malignancies \[[@b10-bjmg-14-02-17],[@b14-bjmg-14-02-17],[@b21-bjmg-14-02-17]\].

We speculate that the conflicting results can be explained with the difference in the proportion of patients who had *amp c-MYC* or *amp MLL* in different series. The absence of the gene *amp* can be logically connected with the early evolutionary stage of the disease and with the cohort of early diagnosed patients. If during the investigation, the later diagnosed patients with *amp c-MYC* or *amp MLL* predominate, a worse prognostic effect may be expected.

All of our AML patients with +8 and *amp c-MYC* had a short OS (about 3.7 months) without hematological remission as well as the patients with +11 and *amp MLL* (about 2.4 months). Two of our MDS patients with expansion of the tri- and tetrasomy 8 cell clones had *amp c-MYC*. Both of them demonstrated a resistance to chemotherapy, disease progression and transformation to AML. In contrast, two of the five patients with +8 without *amp c-MYC*, achieved hematological remission and one on them is still alive. We suppose that appearance of +8 and +11 in karyotype provoke the further developmental events such as *amp c-MYC* or amp MLL that leads to therapy resistance. The earlier patients with +8 and/or +11 are diagnosed, the higher are their chances not to have amp c-MYC or amp MLL and not to be resistant to treatment.

According to the results in our comparatively small patient group, we can assume that *amp c-MYC* and *amp MLL* are natural developmental events, especially in cases with an aggressive expansion of the aberrant cell clone and appearance of additional chromosome anomalies.

###### 

Cytogenetic and molecular genetic findings, achievement of complete remission and overall survival in patients with acute myeloid leukemia or myelodyplastic syndromes and trisomy 8.

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  \#   Sex-Age   (FAB) D~X~   Karyotype                                                                                                                                                                           FISH Results (c-MYC oncogene)              CRD (months)                                       OS (months)
  ---- --------- ------------ ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------ -------------------------------------------------- ------------------------------------------------
  1    F-62      AML-M4       47,XX,+8 \[2\](10%)/46,XX \[18\](90%)                                                                                                                                               2Cs--86%; 3Cs--14%                         no                                                 1[a](#tfn2-bjmg-14-02-17){ref-type="table-fn"}

  2    F-74      AML-M0       47,XX,+8 \[4\](27%)/46,XX \[11\](73%)                                                                                                                                               2Cs--22%; 3Cs--78%                         no                                                 6

  3    M-62      AML-M4       47,XY,+8 \[3\](15%)/46,XY \[17\](85%)                                                                                                                                               2Cs--91%; 3Cs--9%                          9                                                  \>11

  4    M-73      AML-M0       47,XY,+8 \[5\](33%)/46,XY \[10\](67%)                                                                                                                                               2Cs--91%; 3Cs--9%                          no                                                 4

  5    F-26      AML-M5a      47,XX,+8 \[12\](60%)/47,XX,add(4)(p16),+8 \[8\](40%)                                                                                                                                2Cs--8%; 3Cs--92%                          6                                                  11

  6    F-28      AML-M4       47,XX,+8 \[19\](95%)/46,XX \[1\](5%)                                                                                                                                                2Cs--39%; 3Cs--55%; 4Cs--6%                no                                                 3

  7    M-65      AML-M4       47,XY,+8 \[12\](80%)/46,XY \[3\](20%)                                                                                                                                               2Cs--15%; 3Cs--77%; 4Cs--8%                no                                                 6

  8    M-70      AML-M4       47,XY,+8 \[10\](50%)/48,XY,+8,+8 \[6\](30%)/46,XY \[4\](20%)                                                                                                                        2Cs--18%; 3Cs--42%; 4Cs--32%; \>5Cs--8%    no                                                 6

  9    F-16      MDS-RAEB\    ND\                                                                                                                                                                                 2Cs--30%; 3Cs--27%; 4Cs--42%; \>5Cs--1%\   no\                                                15+9\
                 trans AML    48,XX,+8,+8\[20\](100%)                                                                                                                                                             2Cs--28%; 3Cs--14%; 4Cs--46%; \>5Cs--12%   no                                                 9

  10   F-63      MDS-RAEB\    47,XX,+8 \[8\](53%)/46,XX \[7\](47%)\                                                                                                                                               ND\                                        no\                                                10+3\
                 trans AML    47,XX,+8 \[15\](100%)                                                                                                                                                               2Cs--10%; 3Cs--84%; 4Cs--3%; \>5Cs--3%     no                                                 3

  11   M-61      AML-M0       47,XY,dup(1)(p13p32),del(7)(q11q32),+8 \[17\] (100%)                                                                                                                                2Cs--17%; 3Cs--72%; 4Cs--6%; \>5Cs--72%    no                                                 3

  12   M-82      AML-M5b      46,XY,-7,+8 \[5\](28%)/46,XY \[13\](72%)                                                                                                                                            2Cs--32%; 3Cs--48%; 4Cs--13%; \>5Cs--7%    ---[b](#tfn3-bjmg-14-02-17){ref-type="table-fn"}   2

  13   M-68      AML-M4       45--48,X,-Y,-5,-7,+8×2,+9,+15,-16,+mar',+mar" \[15\] (100%)                                                                                                                         2Cs--2%; 3Cs--10%; 3Cs--71%; \>5Cs--17%    no                                                 2

  14   M-62      MDS\         47,XY,+8 \[13\](87%)/48,XY,+8,+19 \[2\](13%)                                                                                                                                        2Cs--9%; 3Cs--80%; 4C--9%; \>5Cs--2%       no                                                 4
                 trans AML                                                                                                                                                                                                                                                                                      

  15   M-61      MDS\         56--59,XY,+1,+2,+4×2,del(5)(q11q31),+6--7,+8×2,del(11)(p13), +15×2,-19+20,+21,+r(?),+mar \[15\] (100%)                                                                              2Cs--14%; 3Cs--54%; 4Cs--18%; \>5Cs--14%   no                                                 1
                 trans AML                                                                                                                                                                                                                                                                                      

  16   M-78      MDS\         46,XY,del(11)(q21q23),del(20)(q11--12) \[2\]/47,XY,+8,t(2;4) (q23;q31),del(11)(q21q23),del(20)(q11--12) \[8\]/46,XY,t(9;22) (q34;q11) \[1\]/47,XY,+8,t(9;22)(q34;q11) \[4\] (80%)   2Cs--17%; 3Cs--75%; 4Cs--5%; \>5Cs--3%     no                                                 4
                 trans AML                                                                                                                                                                                                                                                                                      

  17   M-81      MDR-RARS     47,XY,+8 \[18\]/46,X,-Y,+8,dmin \[2\]/46,XY,del(7)(q21q31) \[2\]/46,XY, \[2\] (83%)                                                                                                 2Cs--17%; 3Cs--76%; 4Cs--5%; \>Cs--2%      ---[b](#tfn3-bjmg-14-02-17){ref-type="table-fn"}   13

  18   F-66      MDS\         45,XX,del(5)(q13),+8,-16,-18 \[6\]/45,idem,del(12)(q22q24) \[11\]/44,XX,del(5)(q13),-7,+8,der(11)t(7;11)(q11;p15),-16,-18 \[8\] (100%)                                              2Cs--88%; 3Cs--12%                         no                                                 3
                 trans AML                                                                                                                                                                                                                                                                                      
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

D~X~ (FAB): Diagnosis (French, American and British classification of hematological diseases); FISH: fluorescent *in situ* hybridization; CRD: complete remission duration; OS: overall survival; AML: acute myeloid leukemia; Cs: composite signal (red+green) detected on the intact *c-MYC* gene; MDS: myelodyplastic syndromes; RAEB: refractory anemia with excess of blasts; trans: transformation; RARS: refractory anemia with ring sideroblasts.

Death due to heart attack before the second induction course.

Patient on supportive care only.

###### 

Cytogenetic and molecular genetic findings, achievement of complete remission and overall survival in patients with acute myeloid leukemia or myelodysplastic syndromes and trisomy 11.

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  \#   Sex-Age   (FAB) D~X~   Karyotype                                                                                                                                                                                                                                                   FISH Results (MLL oncogene)                CRD (months)   OS (months)
  ---- --------- ------------ ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------ -------------- -------------
  1    M-50      AML-M5a      47,XY,+11 \[20\] (100%)                                                                                                                                                                                                                                     2Cs--5%; 3Cs--65%; 4Cs--17%; \>5Cs--13%    no             2

  2    M-74      MDS-RAEB     47,XY,+11 \[11\](55%)/46,XY \[9\](45%)                                                                                                                                                                                                                      2Cs--46%; 3Cs--31%; 4Cs--11%; \>5Cs--12%   no             3

  3    M-75      AML-M4       48,XY,+11×2 \[3\](15%)/46,XY \[17\](85%)                                                                                                                                                                                                                    2Cs--22%; 3Cs--5%; 4Cs--10%; \>5Cs--63%    no             1

  4    M-64      AML-M6       45,XY,−3,−18,+R(?),del(5)q13q33),add(20)(p13) \[2\]/44,XY,−3,−18,del(5)(q13q33),add(11)(q23),add(20)(p13) \[6\]/44,XY,−3,−18,del(5)(q13q33),ins(11;?(q13;?),add(20)(p13 \[9\]/42,XY,−3,−7,−18×2,del(5)(q13q33),ins(11;?)(q13;\>),add(20)(p13) \[9\] (92%)   2Cs--51%; 3Cs--29%; 4Cs--14%; \>5Cs--6%    no             1

  5    M-72      AML-M0       46,XY,del(20)(q11) \[2\]/46,XY,ider(20)(p11.2),del(20)(q11q13) \[4\]/47,idem,+11 \[7\]/46,idem,−Y,+11 \[3\] (62.5%)                                                                                                                                         2Cs--13%; 3Cs--79%; 4Cs--8%                no             6

  6    M-47      MDS\         46,XY,del(12)(p11p12) \[4\]/46,XY,del(12)(p11p12),del(13) (q13q22) \[2\]/46,XY,+11,−17,ins(1)(p13q21q32),der(9),t(9;17) (q10;q10),del(13)(q13q22),del(16)(q22) \[3\]/46,XY \[11\] (15%)                                                                     2Cs--71%; 3Cs--21%; 4Cs--8%                no             6
                 trans AML                                                                                                                                                                                                                                                                                                                          

  7    F-66      AML-M0       44,XX,−7,−11p+,−17,+18,+mar \[7\]/44--45,XX,−3,+6,−7,11p+,add (14)(q32),−16,+18,+22,+mar \[6\] (100%)                                                                                                                                                       2Cs--84%; 3Cs--10%; 4Cs--3%; \>5Cs--3%     no             2

  8    M-69      MDS-RAEB     56--80,XYY,−X,del(5)(q13),t(7;11)(q32;q12),del(13)(q13q32), +2mar \[4\]/81--83,XYY,−X,del(5)(q13),t(7;11)(q32;q12),del(13) (q13q32),t(14;14)(q10;q10),t(21;21)(q10;q10),+2mar \[9\] (100%)                                                                  2Cs--5%; 3Cs--28%; 4Cs--52%; \>5Cs--15%    no             1
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

D~X~ (FAB): Diagnosis (French, American and British classification of hematological diseases); FISH: fluorescent *in situ* hybridization; CRD: complete remission duration; OS: overall survival; AML: acute myeloid leukemia; Cs: composite signal (red+green) detected on the intact *c-MYC* gene; MDS: myelodyplastic syndromes; RAEB: refractory anemia with excess of blasts; trans: transformation.
